Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)

TipRanksApr 28 11:50 ET · Ratings

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

GlobeNewswireApr 28 07:00 ET

Galapagos CEO Paul Stoffels to Retire; Henry Gosebruch Named SpinCo Chief

MT NewswiresApr 21 17:04 ET

Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsApr 9 19:33 ET · Ratings

BofA Securities Initiates Neumora Therapeutics(NMRA.US) With Sell Rating, Announces Target Price $1

Moomoo NewsApr 2 19:32 ET · Ratings

Express News | Neumora Therapeutics Inc : BofA Global Research Cuts to Underperform From Buy; Cuts Price Objective to $1 From $7

ReutersApr 2 07:07 ET